California Municipal Finance Authority (4594)

Overview

BrightPath Biotherapeutics Co., Ltd., based in Tokyo, Japan, is a biopharmaceutical company dedicated to the development of cancer immunotherapy drugs. Since its inception in 2003, originally as GreenPeptide Co., Ltd., the company has focused on advancing the field of cancer treatment through innovative immunotherapy approaches. In July 2017, the company underwent a rebranding to its current name, reflecting a renewed commitment to paving a 'bright path' towards discovering and developing novel therapies for cancer patients. BrightPath Biotherapeutics primarily operates within Japan, aiming to bring transformative cancer treatments from the bench to bedside with a focus on peptide vaccines and targeted therapies for a range of cancer types.

Products and Services

• GRN-1201

  A cancer peptide vaccine candidate currently in Phase II clinical trials for non-small cell lung cancer and Phase I clinical trials for melanoma. GRN-1201 represents BrightPath Biotherapeutics' flagship product, showcasing the company's focus on developing innovative immunotherapies for challenging cancers.

• BP2201

  This product candidate is in Phase I clinical trials and aims to target cancer antigens across various types of cancer. BP2201 exemplifies the company's strategy to develop therapies that are broadly applicable across different cancer indications, potentially providing a versatile approach to cancer treatment.

• BP2301

  Currently in Phase I clinical trials, BP2301 is designed for the treatment of solid tumors, sarcoma, and gynecological cancers. This product candidate highlights BrightPath Biotherapeutics' commitment to addressing less common but equally impactful cancer types through targeted therapy.

• Preclinical Candidates

  The company also has several product candidates in preclinical trials, including BP1202 targeting CD39, BP1210 designed to suppress T cell cytotoxicity, BP1212 aiming to inhibit TIM-3 and CD39, BP1209 targeting tumor-specific neoantigens, and BP1200 focusing on CD73. These preclinical endeavors illustrate BrightPath Biotherapeutics' comprehensive approach to cancer therapy, leveraging a wide array of targets to combat the disease from multiple angles.